Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA-Directed Therapy Change vs Standard of Care in Metastatic TNBC
NCT05770531Phase 2Recruiting
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Oct 2023
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in triple-negative breast cancer (TNBC), sponsored by Vanderbilt-Ingram Cancer Center. Started Oct 2023; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05770531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05770531.